This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very prescient cognitions, friend ;-D. Theres a feast for eagle eyed longs here, no doubt.
Meh,Gives me a chance to get some more
I see 3 phases that the VYCO story will pass through as it regards investment opportunity:
-Pre Awarness: This is where we at now. We have a ticker that has been lying quiet, not focusing on IR at all, but just on building massively legit product offering past concept and commercialization into actual initial market penetration in a $20B market. Discerning early adopter investors have the greatest potential for massive upside. This is primordial soup of which the ultra rich are born, like buying AAPL before everyone has heard of the Ipod and MP3. Defintion of a ridiculous bargain. Those who join the long team here are staking their claim before the covered wagons have even started rolling.
-Organic Awareness ground swell. Coming in the very near future. The cream will rise to the top and you can't keep a good man down. As the core long team finds its footing, company begins to find traction in awareness. Still a massive bargain like AAPL pre I-phone. Volume begins to show signs of true potential. Longs who were already in begin to look like old time market gurus and newly minted longs spread the word by every means possible. Buyin becomes more competive and some even begin to take profit on taste a reward of their foresight. This is the time when orchestrated IR is like the the first arresting notes your soul craves in a symphony promising beautiful crescendos. Long team has grown past a very prescient group of market early adopter gurus to a whole network of respected market mavens with reputation for getting in when the getting is good.
-Mature Market success story, mainstream attention and whole series of increasing successful IR campaigns brings in the consistent volume and PPS jumps that makes the chart look like the hills rising from the plains to the, foothils, to one dizzying peak in the clouds to the next. Ipad anyone? General public now cannot ignore whats happening and the average Joe investor is asking self: why do I always here about this stuff after the millionaires are made? Institutionals are actively trading. Deserved volume becomes a staple of options traders and the conservative longs begin their strategy of buying in the dips and adding to retirement portfolios. Early adopter gurus take profits to buy their yachts and summer homes, Mavens to buy wife a new car.
Bottom line: This is the time to get in. If you shoot at some food and bubbling crude comes up, sell the jalopey and buy the back 40 before Exxon comes knocking. Beverly hills is a'waiting.
VYCO ACTION BUILDING!!! NOW 12x's avg volume and up 65%
VYCO: Hope you've read this, you'll understand why we are long and strong:
VYCO VOLUME update! 10x's the average!
10X's the average volume! Some heavy hitter just took your advice
~VYCO~If you don't you'll wish you did! up 62%. $10B industry FDA Sanctioned, Strong Patents on technology that can make the blind see. THINK ABOUT IT! Inoperable patients are being saved! Investment analysis calling for 5bagger at least, possible 15X... http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
~VYCO~ ON YOUR MARK!! 3x's avg volume, up 62%. $10B industry FDA Sanctioned, Strong Patents on technology that can make the blind see. THINK ABOUT IT! then read this... http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
~VYCO~ Drivers Start your engines!! 3x's avg volume, up 62%. $10B industry, 3,000 surgeries already performed. Strong Patent protection on FDA approved technology that can make the blind see!!! http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Lovin VYCO, true organic LONG play in the making. Open your eyes friends, this is one in a million. If you haven't read this report yet, don't self sabotage and blow it off, you will be reading why retirement might be sooner than you think:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
~VYCO~ RED ALERT!! 3x's avg volume, up 62%. $10B industry, Strong Patent protection on FDA approved technology that can make the blind see!!! http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
I wouldn't expect less with 200% increase in revenues. There's so much upside potential here. The Harbinger Investment report was calling for a potential of 15X pps increase
VYCO: Don't get caught in the dark on this one
Summary and Investment Opportunity
• $1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
• ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
• The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
• We Believe an Investment in Vycor is Somewhat Risky but Has Exceptional Potential
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
VYCO Investment Analysis:
Well the thing is I detect no pump, no email campaign, no big push. VYCO seems to be focusing on spending their capital on penetrating their markets with their product offering. But I have been sensing an organic rising tide of saavy investors watching from the wings. The VYCO offering is so legit, it sets itself apart from 99.99% of the pennyland spinmachines. Some heavy hitters are signing up to play, and their organic networks are rubber necking to find out why. Let them spend a moment with VYCO DD and we should begin to see some fun movement
I'm actually especially encouraged to see the way VYCO awareness is building in such an organic way, as opposed to the manufactured 1 week campaign kind of deal that can only spell pop and drop. Grass roots momentum has always spelled the longest rising biggest gains for me in the past.
Hello VYCO fans! What will today hold in store? Organic awareness seems to be building here. I anticpate a dambreaking soon
I'm discerning three phases, (sorry not 5!) that the VYCO success story will pass through as it regards investment opportunity:
-Pre Awarness: This is where we at now. We have a ticker that has been lying quiet, not focusing on IR at all, but just on building massively legit product offering past concept and commercialization into actual initial market penetration in a $20B market. Chartist wonder what the fuss is about, and a few lucky newcomers shakily take their stand. Discerning early adopter investors have the greatest potential for massive upside. This is primordial soup of which the ultra rich are born, like buying AAPL before everyone has heard of the Ipod and MP3. Defintion of a ridiculous bargain. Those who join the long team here are staking their claim before the covered wagons have even started rolling.
-Organic Awareness ground swell. Coming in the very near future. The cream will rise to the top and you can't keep a good man down. As the core long team finds its footing, company begins to find traction in awareness. Still a massive bargain like AAPL pre I-phone. Volume begins to show signs of true potential. Longs who were already in begin to look like old time market gurus and newly minted longs spread the word by every means possible. Buyin becomes more competive and some even begin to take profit on taste a reward of their foresight. This is the time when orchestrated IR is like the the first arresting notes your soul craves in a symphony promising beautiful crescendos. Chartists are all abuzz. Long team has grown past a very prescient group of market early adopter gurus to a whole network of respected market mavens with reputation for getting in when the getting is good.
-Mature Market success story, mainstream attention and whole series of increasing successful IR campaigns brings in the consistent volume and PPS jumps that makes the chart look like the hills rising from the plains to the, foothils, to one dizzying peak in the clouds to the next. Ipad anyone? General public now cannot ignore whats happening and the average Joe investor is asking self: why do I always here about this stuff after the millionaires are made? Institutionals are actively trading. Deserved volume becomes a staple of options traders and the conservative longs begin their strategy of buying in the dips and adding to retirement portfolios. Early adopter gurus take profits to buy their yachts and summer homes, Mavens to buy wife a new car.
Bottom line: This is the time to get in. If you shoot at some food and bubbling crude comes up, sell the jalopey and buy the back 40 before Exxon comes knocking. Beverly hills is a'waiting.
Message me to chat and strategize more, teammates!
I'm discerning three phases that the VYCO story will pass through as it regards investment opportunity:
-Pre Awarness: This is where we at now. We have a ticker that has been lying quiet, not focusing on IR at all, but just on building massively legit product offering past concept and commercialization into actual initial market penetration in a $20B market. Discerning early adopter investors have the greatest potential for massive upside. This is primordial soup of which the ultra rich are born, like buying AAPL before everyone has heard of the Ipod and MP3. Defintion of a ridiculous bargain. Those who join the long team here are staking their claim before the covered wagons have even started rolling.
-Organic Awareness ground swell. Coming in the very near future. The cream will rise to the top and you can't keep a good man down. As the core long team finds its footing, company begins to find traction in awareness. Still a massive bargain like AAPL pre I-phone. Volume begins to show signs of true potential. Longs who were already in begin to look like old time market gurus and newly minted longs spread the word by every means possible. Buyin becomes more competive and some even begin to take profit on taste a reward of their foresight. This is the time when orchestrated IR is like the the first arresting notes your soul craves in a symphony promising beautiful crescendos. Long team has grown past a very prescient group of market early adopter gurus to a whole network of respected market mavens with reputation for getting in when the getting is good.
-Mature Market success story, mainstream attention and whole series of increasing successful IR campaigns brings in the consistent volume and PPS jumps that makes the chart look like the hills rising from the plains to the, foothils, to one dizzying peak in the clouds to the next. Ipad anyone? General public now cannot ignore whats happening and the average Joe investor is asking self: why do I always here about this stuff after the millionaires are made? Institutionals are actively trading. Deserved volume becomes a staple of options traders and the conservative longs begin their strategy of buying in the dips and adding to retirement portfolios. Early adopter gurus take profits to buy their yachts and summer homes, Mavens to buy wife a new car.
Bottom line: This is the time to get in. If you shoot at some food and bubbling crude comes up, sell the jalopey and buy the back 40 before Exxon comes knocking. Beverly hills is a'waiting.
Message me to chat and strategize more, teammates!
Revenue Up 207% Over 2010 Including Contribution From NovaVision; Vycor Medical Division Revenue Up 78% Over 2010; Vycor Makes First Vycor Shipment to ChinaPress Release: Vycor Medical, Inc. – Tue, Apr 3, 2012 8:00 AM EDT
BOCA RATON, FL--(Marketwire -04/03/12)- Vycor Medical, Inc. ("Vycor") (OTC.BB: VYCO.OB - News) has reported 2011 revenue of $971,367, a 207% increase on the $316,450 for 2010. The Vycor Medical division generated revenue of $548,463, a 78% increase on 2010, and NovaVision generated revenue of $422,904, compared to $8,868 for just one month in 2010. The gross profit for 2011 was $795,109 compared to $267,713 in 2010. The overall group margin was 82% in 2011 compared to 85% in 2010; this reflects the addition of NovaVision and both a change in sales mix at Vycor and the cost of a packaging life extension program.
Group Highlights for 2011
2011 saw Vycor achieve some important milestones in a year of significant development:
Restarting the operations of NovaVision, which had been acquired out of Chapter 7 bankruptcy in late 2010
Merging the operations of Vycor and NovaVision onto one site in Boca Raton, Florida
Closing Common and Preferred stock offerings totaling $4 million
Acquisition of Sight Science Limited in the UK (closed January 4, 2012)
Granting or issuance of 7 additional patents, bringing the Group portfolio (including Sight Science) to 30 granted/issued and 30 pending
The Vycor Medical division made strong advances in 2011, particularly in the final quarter. Penetration into US hospitals and adoption by surgeons has continued to grow as the surgeon community becomes increasingly aware of the minimally invasive nature of Vycor's VBAS and its other clinical benefits. Internationally Vycor also made strong headway, with international sales accounting for approximately 39% of total sales in 2011 compared to 20% in 2010. Highlights for the Vycor Medical division include:
Growth in US hospital approvals in 2011 with the growth continuing in the first quarter of 2012
Grant of SFDA approval to market VBAS in China in December 2011, and the shipment of a first order to China of $170,000; this has been followed by the placing of a second order of similar size in the first quarter of 2012
Grant of registration for VBAS in Japan, with a first order being placed in the first quarter of 2012
Gaining regulatory approval in Australia and applying for regulatory approval in Russia and Korea
Grant or issuance of patents for Russia and China
Publication of three important peer review clinical studies by leading surgeons in key neurosurgery journals
NovaVision also made strong advances in 2011, although it remains a development stage business. Highlights include:
Restarting the operations of NovaVision, which had been acquired out of Chapter 7 bankruptcy in late 2010. This involved re-opening the premises, hiring staff, re-applying for licenses required to deliver medical devices into the home, re-establishing contacts with physicians and recommencing a sales, marketing and patient management process
Creation of a Scientific Advisory Board of highly respected scientists and academics who are leaders in their field: Alvaro Pascual-Leone, Professor of Neurology at Harvard Medical School and Director of Research at the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center; Jason S. Barton, Professor of Neurology, Ophthalmology and Visual Sciences, University of British Columbia and Jose Romano, Chief of Stroke Division and Associate Professor of Neurology at the University of Miami Miller School of Medicine
Grant or issuance of 3 patents in the US and patents in China and Canada.
Acquisition of Sight Science Limited (closed January 4, 2012), a highly complementary business for NovaVision. The combination of the therapies, technologies and knowhow of NovaVision and Sight Science is a key element for the development and growth of NovaVision in the future
Appointment of Prof. Arash Sahraie as NovaVision's Chief Scientific Officer as a part of the Sight Science acquisition. Arash is Professor and Chair in Vision Sciences at the University of Aberdeen, Scotland
Oops, that would be hard *not* to warm up to, if I catch your meaning correctly my friend, pardon my correction ;-D
Welcome Aeschylus1! The report at this link is a great place to start: http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO: 21 patents issued and 30 pending. Good stuff!
From the VYCO website:
You might want to suss into your analysis that VYCO revenues increased last year 200%. Also I have some questions about the float, the OS is 840 million, 65% insider holding, I want to dig deeper there.
Good Morning VYCO land! What's in store today? Hopefully some eyes turned on the story here and some needed volume.
Agreed. A few more eyes is all this needs.
Been reading about VYCO international market penetration. VERY impressive:
The sleeper is rousing! Nice to see a little volume coming in.
Prepromo my friend.
Also, did you see that Harbinger research has VYCO with a projections of .05. That's a five bagger from here.
Well, that's the definition of "hidden gem" You know me, I prefer to get in BEFORE the herd.
So much to like about VYCO: 1st off check out their latest PR's:
http://finance.yahoo.com/news/vycor-medical-inc-reports-first-130000889.html
http://finance.yahoo.com/news/harbinger-research-releases-research-report-175800551.html
Revenues double since last year, a $20B worldwide market with little competition, patented technology with patent protection internationally in countries with huge markets, orders and shipments to Asia. I'm still sussing out all the details but I sniff an investors feast cooking!